Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline

Australian and New Zealand Journal of Psychiatry

Volumn 36, Issue 3, 2002, Pages 384-391

  Joyce, Peter R ^a   Mulder, Roger T ^a   Luty, Suzanne E ^a   Sullivan, Patrick F ^a   McKenzie, Janice M ^a   Abbott, Robyn M ^a   Stevens, Isobel F ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Age; Atypical depression; Fluoxetine; Gender; Major depression; Nortriptyline

Indexed keywords

ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; NORTRIPTYLINE; PHENELZINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DEMOGRAPHY; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROBIOLOGY; OUTCOMES RESEARCH; OUTPATIENT; PREDICTION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYMPTOM; PREDICTION AND FORECASTING; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; REMISSION; TIME; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER; FEMALE; FLUOXETINE; HUMAN; MALE; NORTRIPTYLINE; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; REMISSION INDUCTION; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; TREATMENT OUTCOME; HUMANS;

EID: 0035987702     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1614.2001.01026.x     Document Type: Article

References (34)

1. The long-term outcome of depressive illness
2. Long-term outcome of episodes of major depression
3. The definition and operational criteria for treatment outcome of major depressive disorder: A review of the current research literature
4. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: Remission, recovery, relapse, and recurrence
5. Effects of exclusion criteria in depression treatment studies
6. Family history of depression in clinic and community samples
7. Predictors of drug response in depression
8. Temperament predicts clomipramine and desipramine response in major depression
9. The hypothalamic-pituitary-thyroid axis in major depression
10. The structured clinical interview for DSM-III-R (SCID): I. history, rationale, and description
11. A new depression scale designed to be sensitive to change
12. A rating scale for depression
13. Defining melancholia: Properties of a refined sign-based measure
14. SCL-90-R administration, scoring and procedures manual
15. Assessment of social adjustment by patient self-report
16. A psychobiological model of temperament and character
17. The parental bonding instrument: Psychometric properties reviewed
18. Development and validation of the dysfunctional attitudes scale: A preliminary investigation
19. Development of a scale to measure interpersonal sensitivity
20. Gender differences in treatment response to sertraline versus imipramine in chronic depression
21. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: A meta-analysis
22. Initial antidepressant choice in primary care: Effectiveness and cost of fluoxetine versus tricyclic antidepressants
23. Effect of antidepressant therapy on health care utilization and costs in primary care
24. Adequacy and duration of antidepressant treatment in primary care
25. Chronicity of depressive episode in relation to antidepressant-placebo response
26. The validity of atypical depression in DSM-IV
27. Predictive value of symptoms of atypical depression for differential drug treatment outcome
28. Relevance of DSM-III depressive subtype and chronicity of antidepressant efficacy in atypical depression: Differential response to phenelzine, imipramine, and placebo
29. Fluoxetine versus phenelzine in atypical depression
30. Serotonergic antidepressants are superior to noradrenergic antidepressants in depressed young adults
31. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression
32. Are the newer antidepressant drugs as effective as established physical treatments? Results from an Australasian clinical panel review
33. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia
34. Treatment research at the crossroads: The scientific interface of clinical trials and effectiveness research